tradingkey.logo
tradingkey.logo
Search

Dyadic International Inc

DYAI
Add to Watchlist
1.020USD
+0.124+13.84%
Close 07/01, 16:00ETQuotes delayed by 15 min
37.17MMarket Cap
LossP/E TTM

Dyadic International Inc

1.020
+0.124+13.84%
View Detailed Chart
TradingKey 图表
Intraday
1m
30m
1h
D
W
M
D

Today

+13.84%

5 Days

+39.53%

1 Month

+31.44%

6 Months

+8.51%

Year to Date

+8.51%

1 Year

+5.15%

Key Figures
0.930Open
1.030High
310.18KVolume
LossP/E TTM
33.08P/E Dynamic
--Dividend TTM
0.85%Turnover Ratio
0.896Prev. Close
0.895Low
247.77KTurnover
LossP/E Static
-91.16P/B
0.00%Div Yield TTM
-92.86%ROA
1.34652wk High
1.18Volume Ratio
-5.81MNet Profit
36.44MShares
-0.2116EPS TTM
1.13Beta
-2826.92%ROE
0.65552wk Low
15.07%Amplitude
28.72%Gross Margin
37.17MMarket Cap
6.38Reward/Risk
4.69%Risk Rate

Key Insights

Dyadic International Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 95 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dyadic International Inc's Score

Industry at a Glance

Industry Ranking
95 / 387
Overall Ranking
213 / 4564
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Dyadic International Inc Highlights

StrengthsRisks
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Growing
The company is in a growing phase, with the latest annual income totaling USD 3.09M.
Overvalued
The company’s latest PE is -4.82, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 5.82M shares, decreasing 21.67% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.60.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
6.000
Target Price
+569.64%
Upside Space

Dyadic International Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Dyadic International Inc Info

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Ticker SymbolDYAI
CompanyDyadic International Inc
CEOEmalfarb (Mark A)
Websitehttps://dyadic.com/

FAQs

What is the current price of Dyadic International Inc (DYAI)?

The current price of Dyadic International Inc (DYAI) is 1.02.

What is the symbol of Dyadic International Inc?

The ticker symbol of Dyadic International Inc is DYAI.

What is the 52-week high of Dyadic International Inc?

The 52-week high of Dyadic International Inc is 1.35.

What is the 52-week low of Dyadic International Inc?

The 52-week low of Dyadic International Inc is 0.65.

What is the market capitalization of Dyadic International Inc?

The market capitalization of Dyadic International Inc is 37.17M.

Is Dyadic International Inc (DYAI) currently rated as Buy, Hold, or Sell?

According to analysts, Dyadic International Inc (DYAI) has an overall rating of Buy, with a price target of 6.00.

What is the Earnings Per Share (EPS TTM) of Dyadic International Inc (DYAI)?

The Earnings Per Share (EPS TTM) of Dyadic International Inc (DYAI) is -0.23.